HLB Pep has appointed Lee Wonjik, former CEO of Lotte Biologics, as its new president.


President Lee Wonjik. HLB Pep

President Lee Wonjik. HLB Pep

View original image

According to HLB Pep on November 17, President Lee will lead efforts to expand overseas business and establish production and quality systems that meet global standards.


Lee is a biopharmaceutical expert with experience in quality, production, business operations and corporate management at Bristol Myers Squibb (BMS) in the United States, Samsung Biologics and Lotte Biologics.


Lee majored in molecular and cell biology at the University of California, Berkeley (UC Berkeley), and was responsible for quality operations at BMS in the United States. He later joined Samsung Biologics as a founding member, where he spent about 11 years building the drug substance production organization and serving as head of the drug product (DP) business division. After working on the New Growth Team at Lotte Holdings, he was appointed the first CEO of Lotte Biologics in 2022. He led the acquisition of BMS's Syracuse plant in the United States, helping launch the company and establish its business foundation.


Drawing on President Lee's experience in the global pharmaceutical and biotech industries, HLB Pep plans to focus on securing overseas customers and establishing production and quality systems that meet global standards. On this basis, it aims to significantly expand overseas exports of peptide active pharmaceutical ingredients (APIs). In particular, its strategy is to strengthen partnerships with global pharmaceutical companies and secure new customers, while developing its Osong plant into a global peptide API production hub.



In a message to employees upon taking office, Lee said, "HLB Pep has built technological expertise and production capabilities in the peptide active pharmaceutical ingredients field. We will strengthen our quality systems to meet global regulatory standards and build trust with overseas customers, establishing ourselves as an active pharmaceutical ingredient supply partner to global pharmaceutical companies."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing